10/22/2026
Neurosom is excited to announce that our CEO, Viral Sheth, will attend the CTAD Clinical Trials on Alzheimer's Disease Conference, November 16-19, 2026, in Boston. This year’s program emphasizes Phase I–III clinical trials and blood-based biomarkers, topics that closely align with Neurosom’s NIA-funded clinical trial efforts. The conference focus also complements our innovative closed-loop therapy, designed to enhance glymphatic flow and facilitate the clearance of harmful metabolic waste linked to Alzheimer’s disease.
https://lnkd.in/g9dhBPt7
Visit us: https://www.neurosom.net/